Factors Affecting Attitudes towards COVID-19 Vaccination: An Online Survey in SloveniaArticle Published on 2021-03-122022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] addressed Affect Attitude comparable conducted COVID-19 COVID-19 vaccination COVID-19 vaccine cross-sectional Cross-sectional studies died Europe Factor Generalizability hospitalised immune system Influenza information Intention less men Nurse Older ordinal regression physician potential limitation public opinion question Questionnaires reported SARS-CoV-2 Side effect Slovenia survey surveys and questionnaires the vaccine Trust vaccination Vaccinations Vaccine Vaccine hesitancy Vaccines while [DOI] 10.3390/vaccines9030247 PMC 바로가기 [Article Type] Article
Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidatesArticle Published on 2021-03-112022-10-04 Journal: Scientific Reports [Category] SARS, 유전자 메커니즘, [키워드] absence added Analysis antibody production Antibody-dependent enhancement applied B cell response B cell responses BALB/c mice candidate candidate vaccine caused COVID-19 outbreak Diseases effective Efficacy Efficacy and safety GM-CSF Health humanized immunology in vitro in vivo inactivated Inactivated vaccine infective mice Microbiology morbidity and mortality neutralization capacity Pathogenesis peptide pool performed Preclinical reducing reported SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 virus T cell T cell response the vaccine Toxicity Vaccine vaccine candidate virus [DOI] 10.1038/s41598-021-83930-6 PMC 바로가기 [Article Type] Article
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies Research Published on 2021-03-112022-10-05 Journal: Nature [Category] SARS, 변종, 유전자 메커니즘, 진단, [키워드] affected amino acid change antibody B.1.1.7 B.1.1.7 variant BNT162b2 vaccine COVID-19 Decreased E484K Efficacy eight ENCODE exhibited expressed immune response immunization individual monoclonal antibody mRNA mRNA-based vaccine mutated Mutation N-terminal domain neutralization Neutralizing Neutralizing activity Neutralizing antibody response Patient pseudovirus receptor-binding motif recognize reduced reduction reported SARS-CoV-2 SARS-CoV-2 B.1.1.7 sera Spike protein the receptor-binding domain the vaccine titre transmission potential vaccination Vaccine variant virus VoC wild-type [DOI] 10.1038/s41586-021-03412-7 [Article Type] Research
Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and InfectionVaccines and Antiviral Agents Published on 2021-03-102022-10-30 Journal: Journal of Virology [Category] COVID-19, [키워드] 229E acute respiratory syndrome Antibody Response Betacoronavirus binding common cold coronavirus CoV CoVs cross-react cross-reactive cross-reactivity DNA expressing facilitate full-length spike protein highlight HKU1 Humoral immunity immunization implication induce Infection macaque Neutralizing Neutralizing antibodies Neutralizing antibody response NHPs NL63 observation OC43 other coronavirus other coronaviruses pandemic polyclonal profile pseudoviruses RBD reactivity Receptor binding domain response rhesus macaque rhesus macaques robust sarbecovirus SARS-CoV-1 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine serum similarity Spike protein Spike proteins the SARS-CoV-2 the vaccine vaccination Vaccine Vaccines was reduced [DOI] 10.1128/JVI.00117-21 PMC 바로가기 [Article Type] Vaccines and Antiviral Agents
Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptanceRandomized Controlled Trial Published on 2021-03-092022-10-05 Journal: Proceedings of the National Academy of Sciences of [Category] 임상, [키워드] absence benefit conducted conjoint analysis coronavirus COVID-19 COVID-19 pandemic COVID-19 vaccine Decision analysis Effect effective Effectiveness Efficacy expected experimental design Factor Factors Fever influence Interaction interaction effect likelihood National outcome permanent paralysis Probability receiving remained Replication reported Safe safety profile serious adverse reaction Serious adverse reactions Side effect Side effects significant effect significant increases in significantly the vaccine vaccination Vaccine Vaccine acceptance [DOI] 10.1073/pnas.2021726118 PMC 바로가기 [Article Type] Randomized Controlled Trial
The BCG Vaccine for COVID-19: First Verdict and Future DirectionsImmunology Published on 2021-03-082022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] acute respiratory syndrome administer Administered bacille Calmette-Guérin BCG BCG vaccination bcg vaccine Care catastrophic characterized clinical trials coronavirus cost-effective intervention country cross-protection cross-protective decrease direction Diseases dose Effect effort Epigenetic explained Future Health health system highlighting immune responses Immunity inflammatory cytokine production innate immune memory Macrophage mitigate offer overcome pandemic Prophylactic proportion reported respiratory infections respiratory infectious disease SARS-CoV-2 SARS-COV-2 infection Sickness the vaccine this new coronavirus trained immunity Treatment Tuberculosis vaccinate vaccination Vaccine vaccine for COVID-19 [DOI] 10.3389/fimmu.2021.632478 PMC 바로가기 [Article Type] Immunology
Racism, disease, and vaccine refusal: People of color are dying for access to COVID-19 vaccinesPerspective Published on 2021-03-082022-10-28 Journal: PLoS Biology [Category] COVID-19, SARS, [키워드] concern COVID COVID-19 vaccine disease focus lack racism refusal the disease the vaccine Vaccinations Vaccine [DOI] 10.1371/journal.pbio.3001167 PMC 바로가기 [Article Type] Perspective
COVID-19 vaccines: rapid development, implications, challenges and future prospectsCOVID-19 백신: 빠른 개발, 의미, 도전 및 미래 전망Review Published on 2021-03-072022-08-31 Journal: Human Cell [Category] 신약개발, [키워드] accelerated addition affected America approved authorization Canada China clinical development complications COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccine development COVID-19 vaccines Distributing Emergency Emergency use authorization EUA example Government Healthcare system Healthcare systems Implications include India mitigate pandemic raised Russia Safe SARS-CoV-2 South Africa Spread strain the vaccine therapy for COVID-19 United Kingdom United State United States USA vaccination Vaccine vaccine candidates vaccine developers Vaccine development Vaccine hesitancy Vaccines [DOI] 10.1007/s13577-021-00512-4 PMC 바로가기 [Article Type] Review
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2Original Article Published on 2021-03-072022-10-31 Journal: Clinical & Translational Immunology [Category] COVID-19, [키워드] ACE ACE‐2 ACE2 African antibody Antibody Response antigenic approach asked B‐cell binding blocked Blood Contact convalescent patient Convalescent patients COVID‐19 defined disease effective enzyme epitope exacerbate Identified identify immune response immunogens immunopathology induce Interaction memory B cells mice neutralising neutralising antibody objective overlapping peptide peptide epitopes peptides plasma Prevent Protein raised RBD receptor‐binding domain receptor‐binding domain reduced risk Region Result safety profile SARS‐CoV‐2 SARS‐CoV‐2‐specific antibody SARS‐CoV‐2 sera significantly South specificity Strains T‐cell responses tested tetramer staining the RBD the Spike the vaccine vaccinate Vaccine Vaccine development [DOI] 10.1002/cti2.1260 PMC 바로가기 [Article Type] Original Article
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials단회 투여 및 ChAdOx1 nCoV-19(AZD1222) 백신의 면역원성 및 효능에 대한 추가 투여 시간의 영향: 4건의 무작위 시험에 대한 통합 분석Meta-Analysis Published on 2021-03-062022-09-10 Journal: Lancet (London, England) [Category] MERS, SARS, 임상, [키워드] 1:1 95% CI addition administration Ageusia All participants Analysis Anosmia antibody antibody levels Antibody Response Antibody responses approved assigned AstraZeneca AZD1222 baseline binding antibody booster dose booster doses Brazil category ChAdOx1 ChAdOx1 nCoV-19 Clinical research Coalition control group control vaccine cough COV005 COVID-19 COVID-19 disease COVID-19-related death Cutoff death defined described dose doses double-blind Efficacy Emergency use Endpoint Evidence evidence of exclusion exploratory Exploratory analyses Exploratory analysis Fever finding first dose FIVE Follow-up for inclusion foundation funding geometric mean geometric mean ratio GMR had no Hospital admission immunoassay immunogenicity immunogenicity data independent indicated individual Infection initial Innovation interim analysis ISRCTN89951424 less lower dose Medicine Medicines Medicines and Healthcare products Regulatory Agency Melinda Gate Melinda Gates N protein NAAT NAAT-positive swab network neutralisation NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test observation offered Older outcomes Oxford pandemic participant phase 2/3 phase 3 study positive swab primary analysis primary endpoint Primary outcome prime-boost interval priming PROTECT pseudovirus randomised controlled Randomised trial Randomly receive receiving recruited regimen Registered regulatory authority response Safety saline placebo SARS-COV-2 infection SARS-CoV-2 N protein second dose secondary Serious Adverse Events seronegative Seven Shortness of breath single-blind Single-dose South South Africa Standard dose subset supported Swab swabs Symptom symptomatic COVID-19 disease symptomatic infection Telle the primary endpoint the timing the vaccine Trial vaccination Vaccine vaccine efficacy Valley Viral Viral particles [DOI] 10.1016/S0140-6736(21)00432-3 PMC 바로가기 [Article Type] Meta-Analysis